Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!
Decoding the Future of Hematologic Cancer: A First Look at Game-Changing Research from EHA 2024's High Priority Sessions
- Home
- EHA Conference
- hematologic cancer preview content eha 2024
Hematologic Cancer Preview Content | EHA 2024
The EHA congress typically features a diverse range of hematologic disorders, including leukemia, lymphoma, myeloma, bleeding disorders, and hematopoietic stem cell transplantation, offering a comprehensive overview of the current state of both research and clinical practice in hematology. Furthermore, it offers insights into future directions and obstacles in the field.
Top pharmaceutical companies are gearing up for the conference, ready to present initial, updated, and final results. Key players like GlaxoSmithKline, AstraZeneca, Roche, Electra Therapeutics, Novartis, Agios Pharmaceuticals, Sanofi, and others will present High Priority Late Breaking and Plenary Session Abstracts.
These sessions are on the verge of potentially transforming patient care in the future. They carry the potential for substantial progress, aiming to positively impact the treatment landscape of hematologic cancer.
BLENREP (belantamab mafodotin) was initially granted conditional marketing authorization in the US and EU based on results from the DREAMM-2 trial, a Phase II, open-label, randomized, two-arm study, with the primary efficacy measure being the overall response rate (ORR). However, the subsequent Phase III DREAMM-3 trial did not achieve its primary endpoint of progression-free survival (PFS), leading the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) to revoke the conditional marketing authorization. GSK recently published detailed positive results from DREAMM-7 and announced that the DREAMM-8 trial also met its primary endpoint of PFS. So it would be interesting to see the full results from the DREAMM-8 trial as these positive results could mark BLENREP’s potential return as a promising treatment for relapsed refractory multiple myeloma.
Sanofi will also present the data of SARCLISA (isatuximab) from the IMROZ trial, during the plenary scientific session on June 15, selected as one of the top six abstracts to be featured at the congress. Results from IMROZ will form the basis of a future regulatory submission for patients with newly diagnosed multiple myeloma not eligible for transplant.
Key Abstracts
Â
Executive Summary
The EHA congress typically features a diverse range of hematologic disorders, including leukemia, lymphoma, myeloma, bleeding disorders, and hematopoietic stem cell transplantation, offering a comprehensive overview of the current state of both research and clinical practice in hematology.